PlainRecalls
FDA Drug Moderate Class II Terminated

Docetaxel Injection USP 160 mg/8mL (20 mg/mL), For Intravenous Infusion Only, Rx Only, 8 mL Single Use Vial, Cytotoxic Agent, Manufactured by: Shilpa Medicare Limited, India, Distributed by: Armas Pharmaceuticals, Inc., Manalapan, NJ 07726, NDC 72485-216-08.

Reported: December 16, 2020 Initiated: December 8, 2020 #D-0126-2021

Product Description

Docetaxel Injection USP 160 mg/8mL (20 mg/mL), For Intravenous Infusion Only, Rx Only, 8 mL Single Use Vial, Cytotoxic Agent, Manufactured by: Shilpa Medicare Limited, India, Distributed by: Armas Pharmaceuticals, Inc., Manalapan, NJ 07726, NDC 72485-216-08.

Reason for Recall

CGMP Deviations

Details

Recalling Firm
Shilpa Medicare Limited
Units Affected
2008 vials
Distribution
Nationwide in the U.S.
Location
Polepally, Jadcherla, N/A

Frequently Asked Questions

What product was recalled?
Docetaxel Injection USP 160 mg/8mL (20 mg/mL), For Intravenous Infusion Only, Rx Only, 8 mL Single Use Vial, Cytotoxic Agent, Manufactured by: Shilpa Medicare Limited, India, Distributed by: Armas Pharmaceuticals, Inc., Manalapan, NJ 07726, NDC 72485-216-08.. Recalled by Shilpa Medicare Limited. Units affected: 2008 vials.
Why was this product recalled?
CGMP Deviations
Which agency issued this recall?
This recall was issued by the FDA Drug on December 16, 2020. Severity: Moderate. Recall number: D-0126-2021.